Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00334776 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Intraocular Melanoma
Melanoma (Skin)

Interventions

BIOLOGICAL: MART-1 antigen
BIOLOGICAL: gp100:209-217(210M) peptide vaccine
BIOLOGICAL: therapeutic autologous dendritic cells
BIOLOGICAL: tyrosinase peptide

Sponsor

University of Southern California

Collaborators

[object Object]